Startups Plan the Health Data Gold Rush

Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.

| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

ABOVE: © ISTOCK.COM, RICK_JO

Even if you’ve never heard of IQVIA, the company most likely knows some things about you—if only in anonymized form. As Harvard University fellow Adam Tanner documents in his 2017 book Our Bodies, Our Data, IQVIA (formerly IMS Health), along with other companies such as IBM and Lexis-Nexus, regularly pay health care providers, pharmacies, clinical labs, and insurers for patients’ de-identified health records, prescribing data, insurance claims, and other information. Then they collate and sell this information to pharmaceutical companies and others who rely on such data for research and marketing. And business is good: IQVIA reported revenue of $2.5 billion in the second quarter of this year.

Until now, the proceeds from the booming health data–brokering industry have seldom been seen by the people who contribute the information in the first place. But that could be about to change, thanks to a new class of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Shawna Williams

    Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor's degree in biochemistry from Colorado College and a graduate certificate and science communication from the University of California, Santa Cruz.

Published In

October 2018

Bright Lights, Big Problems

Scientists are exploring the ecological damage caused by artificially lit night skies

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio